Psoriatic arthritis (PsA) is a complex and heterogeneous disease in which environmental, and other factors interact resulting in disease in genetically susceptible individuals. PsA can occur in up to 40% of individuals with skin psoriasis leading to significant morbidity and mortality and enormous costs to healthcare systems. Recent advances in knowledge of disease pathogenesis in PsA have come from the use of biologic drugs in the treatment of PsA and skin psoriasis. However, despite good efficacy and safety profile, these drugs have not proven curative. In addition a substantial proportion of affected individuals may lose response to these agents, or develop side effects. The joint intervention of rheumatology and dermatology professionals in the management of these multifaceted diseases may lead to more optimal disease control and improve outcomes.
Disclosure of Interest None declared